Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）

/PRNewswire/ -- On January 9, 2024 (Beijing Time), Abbisko Therapeutics (HKEX code: 02256) announced that its investigational innovative CSF-1R inhibitor...

Related Keywords

Canada ,Taiwan ,Shanghai ,China ,Hong Kong ,Beijing ,Macau ,Chinese , ,European Union ,Abbisko Therapeutics Co Ltd ,European Medicines Agency ,Hong Kong Stock Exchange ,Abbisko Cayman Limited Stock Code ,Beijing Time ,Abbisko Therapeutics ,Priority Medicines ,Break Through Designation ,Fast Track Designation ,Abbisko Cayman Limited ,Stock Code ,Abbisko ,Biotechnology ,Health Care Amp Hospitals ,Pharmaceuticals ,Medical Pharmaceuticals ,